Literature DB >> 10743798

Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

A Zink1, J Braun, J Listing, J Wollenhaupt.   

Abstract

OBJECTIVE: To describe indicators of disability and handicap in the 2 major inflammatory rheumatic diseases rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to estimate the burden of illness in terms of functional status, pain, and global well being, as well as with regard to unemployment and early retirement.
METHODS: Data from the German rheumatological database on 52,444 patients with RA and 8,776 patients with AS seen at 21 collaborative arthritis centers in Germany between 1993 and 1997 were analyzed. To estimate the burden of the 2 diseases at different biographical phases, age and sex matched groups of patients were compared for functional disability, pain, global assessment of health status, education level, and employment status.
RESULTS: For comparable ages, disability in female patients with AS or RA was rated similarly by the physicians (e.g., 61-70 years: 42% severe disability in RA and 44% in AS), whereas men with AS were rated more disabled than men with RA (61-70 years: 35% in RA and 48% in AS). Patients' self-ratings of disability were generally worse for women than for men (age 61-70: women 37% severe disability in RA and 35% in AS, men: 24% in RA and 19% in AS). Pain intensity was rated similarly by women and men with RA and AS at ages < 51 years (33% severe pain at ages 41-50 in men and 34% in women in both diseases). It increased with age in women (> 70 years: 41% severe pain in RA and 44% in AS) and remained stable in men (27% RA and 29% AS > 70 years). At 71.3% the employment rate in AS was clearly higher than in RA (49.5%). There was significant influence of the education level (men 51-60 years with AS: low education 56% employment rate, high education 79%) and the labor market (men 51-55 years with AS: 80% employment rate under good, 59% under bad overall labor market conditions).
CONCLUSION: Age and sex matched groups of patients with RA and AS in tertiary rheumatological care show similar amounts of disability, pain, and reduction in well being. Therefore, the offer of comprehensive care and pain management to both groups should be comparable.

Entities:  

Mesh:

Year:  2000        PMID: 10743798

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  88 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors:  J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Authors:  J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

4.  Employment perspectives of patients with ankylosing spondylitis.

Authors:  A M J Chorus; A Boonen; H S Miedema; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

Review 5.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

6.  Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists.

Authors:  J Sany; P Bourgeois; A Saraux; S Durieux; A Lafuma; J P Daurès; F Guillemin; J Sibilia
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

7.  Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.

Authors:  I Ertenli; S Ozer; S Kiraz; S B Apras; A Akdogan; O Karadag; M Calguneri; U Kalyoncu
Journal:  Rheumatol Int       Date:  2010-11-16       Impact factor: 2.631

8.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

9.  The relationship between depressive symptoms, illness perceptions and quality of life in ankylosing spondylitis in comparison to rheumatoid arthritis.

Authors:  Thomas Hyphantis; Konstantinos Kotsis; Niki Tsifetaki; Francis Creed; Alexandros A Drosos; André F Carvalho; Paraskevi V Voulgari
Journal:  Clin Rheumatol       Date:  2013-01-18       Impact factor: 2.980

Review 10.  [Ankylosing spondylitis. Target treatment criteria].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.